Easy-to-follow guidelines from a pro for simplifying your investments, protecting yourself from the investment sharks and achieving financial freedom Drawing on his years as an investor for leading banks in the U.S. and Asia, Philip Cheng delivers down-to-earth strategies guaranteed to make you "shark-proof" while you optimize...

The book begins with...

“Companies are beginning to conceive, design, develop, and distribute products and services in profoundly new ways…But how to exploit this new connectivity? Read on.”
—From the Foreword by Don Tapscott, bestselling author of Grown Up...

Minor decisions during architecture and design...

Easy to read and comprehensive, Survival Analysis Using SAS: A Practical Guide, Second Edition, by Paul D. Allison, is an accessible, data-based introduction to methods of survival analysis. Researchers who want to analyze survival data with SAS will find just what they need with this fully updated new edition that incorporates the many...

With the globalization of economies and growth of information and communication technologies (ICT), collaboration has become the key to survival. Just like individuals and mankind, business organizations also depend on collaboration for survival and growth.  The concept of departments, committees, teams, etc., which are so fundamental to...

It’s a hacker’s dream come true: over one million Web sites are now vulnerable to attack through recently discovered flaws in the PHP scripting language. So how do you protect your site? In this book, bestselling author Mohammed Kabir provides all the tools...

This is a monograph on the concept of residual life, which is an alternative summary measure of time-to-event data, or survival data. The mean residual life has been used for many years under the name of life expectancy, so it is a natural concept for summarizing survival or reliability data. It is also more interpretable than the popular...

The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The...